[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-350586-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-350586-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","evolving-role-of-biomarkers-beyond-prostate-specific-antigen-in-refining-prostate-cancer-screening-from-blood-based-tests-to-urinary-and-genetic-markers-review","Evolving role of biomarkers beyond prostate-specific antigen in refining prostate cancer screening - From blood-based tests to urinary and genetic markers (Review)","","Prostate-specific antigen (PSA) screening lowers prostate cancer mortality but is constrained by overdiagnosis and insufficient specificity for clinically significant disease. This review evaluates emerging biomarkers that better separate aggressive tumors from indolent lesions, covering advanced blood-based markers (including PSA isoforms, liquid biopsy components, and the Prostate Health Index), urinary biomarkers such as PCA3, TMPRSS2:ERG, and MyProstateScore 2.0, and genetic markers from inherited risk to polygenic scores. It also discusses combining biomarkers with multiparametric MRI and risk-calculator models to improve screening pathways, with future directions in multi-omics, artificial intelligence, and biosensing.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/evolving-role-of-biomarkers-beyond-prostate-specific-antigen-in-refining-prostate-cancer-screening-from-blood-based-tests-to-urinary-and-genetic-markers-review/350586/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/evolving-role-of-biomarkers-beyond-prostate-specific-antigen-in-refining-prostate-cancer-screening-from-blood-based-tests-to-urinary-and-genetic-markers-review/350586.png","ImageObject",300,407,{"name":42,"@type":43},"Blitz","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",15,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is PSA-based prostate cancer screening limited?","Question",{"text":63,"@type":64},"PSA screening can cause overdiagnosis and overtreatment of indolent tumors. It also has poor specificity for clinically significant prostate cancer, leading to unnecessary biopsies and procedural risks.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which blood-based biomarkers are discussed as alternatives or complements to PSA?",{"text":68,"@type":64},"The review covers advanced blood-based markers including PSA isoforms, liquid biopsy components, and the Prostate Health Index (PHI).",{"name":70,"@type":61,"acceptedAnswer":71},"What urinary and genetic biomarker types are included in the review?",{"text":72,"@type":64},"Urinary markers include PCA3, TMPRSS2:ERG fusion, and the MyProstateScore 2.0 panel. Genetic markers range from inherited, high-penetrance alterations to polygenic risk scores, which support risk stratification.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},350586,1790794857,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},24464137899374,"https://us-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","MOLECULAR MEDICINE REPORTS 34: 244, 2026  \nEvolving role of biomarkers beyond prostate‑specific antigen in refining prostate cancer screening: From blood‑based tests to urinary and genetic markers (Review)  \nLUXI LI 1,2 , LINYUE ZHANG 1,2 , ZEHONG LI 1,2 , KEQIANG CHAI 1,2 and WEIDONG REN3  \n1The Urology Center, First People's Hospital of Baiyin City (The Third Affiliated Hospital of Gansu University of Chinese Medicine), Baiyin, Gansu 730900, P.R. China; 2Department of Urology, First People's Hospital of Baiyin City (The Third Affiliated Hospital of Gansu University of Chinese Medicine), Baiyin, Gansu 730900, P.R. China; 3Health Management Center, First People's Hospital of Baiyin City (The Third Affiliated Hospital of Gansu University of Chinese Medicine), Baiyin, Gansu 730900, P.R. China  \nReceived December 24, 2025; Accepted June 11, 2026  \nDOI: 10. 3892/mmr.2026.13954  \nAbstract. Prostate‑specific antigen (PSA) screening reduces prostate cancer (PCa) mortality but is limited by overdiagnosis and poor specificity for clinically significant disease. These limitations drive the need for more accurate biomarkers to distinguish aggressive cancers from indolent lesions . The present review examined advanced blood‑based markers, including PSA isoforms, liquid biopsy components and the Prostate Health Index; urinary biomarkers, such as PCa antigen 3, transmembrane protease serine 2‑v‑ets erythroblastosis virus E26 oncogene homolog fusion and the MyProstateScore 2.0 panel; and genetic markers ranging from high‑penetrance  \nCorrespondence to: Dr Weidong Ren, Health Management Center, First People's Hospital of Baiyin City (The Third Affiliated Hospital of Gansu University of Chinese Medicine), 222 Silong Road, Baiyin, Gansu 730900, P.R. China  \nE‑mail: [5231759891@qq.com](5231759891@qq.com)  \nDr Keqiang Chai, The Urology Center, First People's Hospital of Baiyin City (The Third Affiliated Hospital of Gansu University of Chinese Medicine), 222 Silong Road, Baiyin, Gansu 730900, P.R. China  \nE‑mail: [312306379@qq.com](312306379@qq.com)  \nAbbreviations: PCa, prostate cancer; PSA, prostate‑specific antigen; csPCa, clinically significant prostate cancer; tPSA, total PSA; fPSA, free PSA; PHI, Prostate Health Index; mpMRI, multiparametric magnetic resonance imaging; PCA3, prostate cancer antigen 3; TMPRSS2:ERG, transmembrane protease serine 2‑v‑ets erythroblastosis virus E26 oncogene homolog fusion; MiPS, Mi‑Prostate Score; MPS, MyProstate Score; EPI, ExoDx Prostate (IntelliScore) score; NPV, negative predictive value; CTCs, circulating tumor cells; cfDNA, cell‑free DNA; ctDNA, circulating tumor DNA; GSTP1, glutathione S‑transferase pi 1; PRS, polygenic risk score; DDR, DNA damage repair; EV, extracellular vesicle  \nKey words: PCa, screening, biomarkers, prostate‑specific antigen isoforms, liquid biopsy, urinary biomarkers, genetic markers  \ngermline mutations to polygenic risk scores . It further explored the integration of these biomarkers with multipa‑ rametric MRI, risk‑calculator models and health‑economic evaluations to optimize screening pathways. Future directions involve multi‑omic profiling, artificial intelligence and novel biosensing technologies. The present review aimed to provide a comprehensive and balanced perspective on emerging biomarkers that are reshaping personalized PCa screening.  \nContents  \n1. Introduction  \n2. Blood‑based biomarkers: Refining the serum signature  \n3. Urinary biomarkers: A non‑invasive window to the prostate  \n4. Genetic and polygenic risk markers: Informing inherited susceptibility  \n5. Integrative strategies and clinical decision‑making  \n6. Future directions  \n7. Conclusions  \n1. Introduction  \nGlobally, prostate cancer (PCa) remains a major cause of male cancer morbidity and mortality, with an estimated 1.47 million new cases and 397,000 deaths worldwide in 2022. The age‑standardized incidence rate varies considerably across regions, from ~29.4 per 100,000 globally to 9.7 per 100,000 in China","cbCainjQpcBDYgML","https://ap.wps.com/l/cbCainjQpcBDYgML","pdf",3516076,18,"English","# Introduction\n# Blood-based biomarkers: Refining the serum signature\n# Urinary biomarkers: A non-invasive window to the prostate\n# Genetic and polygenic risk markers: Informing inherited susceptibility\n# Integrative strategies and clinical decision-making\n# Future directions\n# Conclusions","[{\"question\":\"Why is PSA-based prostate cancer screening limited?\",\"answer\":\"PSA screening can cause overdiagnosis and overtreatment of indolent tumors. It also has poor specificity for clinically significant prostate cancer, leading to unnecessary biopsies and procedural risks.\"},{\"question\":\"Which blood-based biomarkers are discussed as alternatives or complements to PSA?\",\"answer\":\"The review covers advanced blood-based markers including PSA isoforms, liquid biopsy components, and the Prostate Health Index (PHI).\"},{\"question\":\"What urinary and genetic biomarker types are included in the review?\",\"answer\":\"Urinary markers include PCA3, TMPRSS2:ERG fusion, and the MyProstateScore 2.0 panel. Genetic markers range from inherited, high-penetrance alterations to polygenic risk scores, which support risk stratification.\"}]","Evolving role of biomarkers beyond prostate-specific antigen in refining prostate cancer screening - From blood-based tests to urinary and genetic markers (Review) | PDF",1790089703,45,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/53bc61f6b5542f4ed41b3e476c2635f5.webp",983,1357,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/85e4875cd890e3d4a93a499826389053.webp",982,1356,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/66f25289846cdc7826bf3f069115ba7d.webp",981,1354,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/87930c425e730f04f81a509de26ae1d5.webp",980,1353]